1. Generics Bulletin
  3. >>Biosimilars

Celltrion Gets Ready To Face The Competition After European Bevacizumab Nod

Vegzelma CT-P16 Biosimilar Rival To Avastin Receives CHMP Positive Opinion

 
• By Dave Wallace

Celltrion has received a positive opinion from the EMA’s CHMP for its Vegzelma bevacizumab biosimilar rival to Avastin, setting up the Korean firm to enter a competitive European market that already includes several bevacizumab biosimilars.

Europe Map Crowd People
Celltrion faces a crowded European market for bevacizumab • Source: Shutterstock

Celltrion has garnered a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use recommending granting a pan-European marketing authorization for the firm’s Vegzelma (bevacizumab) biosimilar rival to Avastin.

Typically, the European Commission acts within 67 days to convert CHMP positive opinions into

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Biosimilars

More from Products

Biocon Biologics Plans To Slow Down After Five Planned Near-Term Biosimilar Launches

 
• By Urtė Fultinavičiūtė

With a lineup of five high-value biosimilars in the wings, Biocon Biologics may be more selective going forward and plans to take a one product per year approach.

Biocon Eyes Fundraising Round Amid Discussions On Merger With Biosimilars Branch

 
• By Urtė Fultinavičiūtė

As financial volatility continues in the industry, Biocon’s board is considering merging its two off-patent drug businesses.

Micro Labs Agrees To 15-Year Freeze On US Bempedoic Acid Rival

 
• By Dean Rudge

Eight more ANDA filers remain in play challenging patents shielding Esperion’s Nexletol (bempedoic acid) after Micro Labs deal out litigation via a settlement agreement.